VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.
Eptinezumab-jjmr is a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Eptinezumab-jjmr has an approximate molecular weight of 143 kD. Eptinezumab-jjmr is produced in Pichia pastoris yeast cells by recombinant DNA technology.
Vyepti is a 30-minute intravenous (IV) treatment given 4 times per year (every 3 months).
The recommended dosage is 100 mg administered by intravenous infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 3 months.
The most common side effects include:
There are several programs patients can sign up for that will assist in treatment costs:
To learn more about this treatment, browse the resources below.
Contact us to chat with one of our helpful scheduling specialists!